Over the past 12 months, 11 insiders at BeOne Medicines Ltd. filed 191 open-market SEC Form 4 transactions on ONC: 0 purchases worth $0 and 191 sales worth $307.0M. Insiders have been net sellers over this period. The most recent filing was on Jul 22, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 22, 26 | Chan Henry LeeSVP, General Counsel | SELL | 1.7K | $325.00 | $542K |
| Jul 21, 26 | John OylerChief Executive Officer, Director | SELL | 20.0K | $320.06 | $6.3M |
| Jul 20, 26 | John OylerChief Executive Officer, Director | SELL | 15.5K | $318.30 | $4.8M |
| Jul 17, 26 | John OylerChief Executive Officer, Director | SELL | 35.8K | $315.06 | $11.2M |
| Jul 16, 26 | John OylerChief Executive Officer, Director | SELL | 42.8K | $323.59 | $13.6M |
| Jul 15, 26 | John OylerChief Executive Officer, Director | SELL | 48.7K | $313.58 | $15.2M |
| Jul 14, 26 | John OylerChief Executive Officer, Director | SELL | 45.9K | $307.57 | $14.1M |
| Jul 13, 26 | John OylerChief Executive Officer, Director | SELL | 26.3K | $307.40 | $8.0M |
| Jul 10, 26 | John OylerChief Executive Officer, Director | SELL | 5.1K | $303.03 | $1.5M |
| Jul 8, 26 | Chan Henry LeeSVP, General Counsel | SELL | 664 | $302.46 | $201K |
| Jun 23, 26 | John OylerChief Executive Officer | SELL | 1.8K | $275.10 | $492K |
| Jun 23, 26 | Lai WangPresident, Global Head of R&D | SELL | 1.1K | $276.74 | $296K |
| Jun 23, 26 | Xiaobin WuPresident and COO | SELL | 1.3K | $276.26 | $357K |
| Jun 16, 26 | Chan Henry LeeSVP, General Counsel | SELL | 590 | $265.98 | $157K |
| Jun 16, 26 | John OylerChief Executive Officer | SELL | 1.7K | $266.69 | $455K |
| Jun 16, 26 | Lai WangPresident, Global Head of R&D | SELL | 1.2K | $265.39 | $310K |
| Jun 16, 26 | Xiaobin WuPresident and COO | SELL | 1.4K | $266.76 | $362K |
| Jun 11, 26 | Titus B. BallPrincipal Accounting Officer | SELL | 120 | $257.53 | $31K |
| Jun 11, 26 | Chan Henry LeeSVP, General Counsel | SELL | 428 | $257.63 | $110K |
| Jun 11, 26 | John OylerChief Executive Officer | SELL | 859 | $258.81 | $221K |
| Jun 11, 26 | Aaron RosenbergChief Financial Officer | SELL | 631 | $257.74 | $163K |
| Jun 11, 26 | Lai WangPresident, Global Head of R&D | SELL | 756 | $261.00 | $197K |
| Jun 11, 26 | Xiaobin WuPresident and COO | SELL | 626 | $261.20 | $164K |
| Jun 8, 26 | Titus B. BallPrincipal Accounting Officer | SELL | 100 | $272.08 | $27K |
| Jun 8, 26 | Chan Henry LeeSVP, General Counsel | SELL | 711 | $271.26 | $192K |
| Jun 8, 26 | John OylerChief Executive Officer | SELL | 3.8K | $271.14 | $1.0M |
| Jun 8, 26 | Lai WangPresident, Global Head of R&D | SELL | 1.3K | $270.73 | $357K |
| Jun 8, 26 | Xiaobin WuPresident and COO | SELL | 1.4K | $270.55 | $389K |
| Jun 1, 26 | Qingqing Yi | SELL | 235 | $279.13 | $66K |
| May 22, 26 | Baker Bros. Advisors Lp | SELL | 2.8K | $23.85 | $66K |
| May 22, 26 | Margaret Dugan | SELL | 212 | $309.60 | $66K |
| May 22, 26 | Alessandro Riva | SELL | 212 | $309.51 | $66K |
| May 22, 26 | Sanders Corazon (corsee) D. | SELL | 212 | $309.59 | $66K |
| May 13, 26 | Chan Henry LeeSVP, General Counsel | SELL | 332 | $310.72 | $103K |
| Apr 8, 26 | Chan Henry LeeSVP, General Counsel | SELL | 332 | $311.59 | $103K |
| Mar 11, 26 | Chan Henry LeeSVP, General Counsel | SELL | 341 | $300.00 | $102K |
| Feb 4, 26 | Chan Henry LeeSVP, General Counsel | SELL | 996 | $350.00 | $349K |
| Jan 7, 26 | Chan Henry LeeSVP, General Counsel | SELL | 664 | $331.76 | $220K |
| Dec 16, 25 | John OylerChief Executive Officer | SELL | 7.5K | $305.24 | $2.3M |
| Dec 15, 25 | John OylerChief Executive Officer | SELL | 16.3K | $314.92 | $5.1M |
| Dec 11, 25 | Chan Henry LeeSVP, General Counsel | SELL | 332 | $325.00 | $108K |
| Dec 10, 25 | Chan Henry LeeSVP, General Counsel | SELL | 332 | $318.28 | $106K |
| Nov 26, 25 | Sanders Corazon (corsee) D.Director | SELL | 1.8K | $342.47 | $620K |
| Nov 17, 25 | Xiaobin WuPresident and COO | SELL | 3.2K | $382.32 | $1.2M |
| Nov 13, 25 | Xiaobin WuPresident and COO | SELL | 4.2K | $381.05 | $1.6M |
| Nov 12, 25 | Chan Henry LeeSVP, General Counsel | SELL | 664 | $350.00 | $232K |
| Nov 12, 25 | Xiaobin WuPresident and COO | SELL | 4.8K | $362.07 | $1.7M |
| Oct 8, 25 | Chan Henry LeeSVP, General Counsel | SELL | 4.7K | $351.12 | $1.7M |
| Sep 16, 25 | John OylerChief Executive Officer | SELL | 12.4K | $327.78 | $4.1M |
| Sep 10, 25 | Chan Henry LeeSVP, General Counsel | SELL | 4.8K | $327.93 | $1.6M |
Over the past 12 months, insiders at BeOne Medicines Ltd. filed 0 open-market purchases worth $0 and 191 sales worth $307.0M on ONC, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 22, 26.
11 different insiders at BeOne Medicines Ltd. filed open-market SEC Form 4 transactions on ONC over the last 12 months.
InsiderTape plots every ONC insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every BeOne Medicines Ltd. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →